Purpose: In patients with COPD, acute exacerbation (AE) is not only an important determinant of prognosis, but also an important factor in choosing therapeutic agents. In this study, we evaluated the usefulness of COPD subtypes identified through cluster analysis to predict the first AE. Patients and methods: Among COPD patients in the Korea COPD Subgroup Study (KOCOSS) cohort, 1,195 who had follow-up data for AE were included in our study. We selected seven variables for cluster analysis -age, body mass index, smoking status, history of asthma, COPD assessment test (CAT) score, post-bronchodilator (BD) FEV 1 % predicted, and diffusing capacity of carbon monoxide % predicted. Results: K-means clustering identified four clusters for COPD that we named putative asthma-COPD overlap (ACO), mild COPD, moderate COPD, and severe COPD subtypes. The ACO group (n=196) showed the second-best post-BD FEV 1 (75.5% vs 80.9% [mild COPD, n=313] vs 52.4% [moderate COPD, n=345] vs 46.7% [severe COPD, n=341] predicted), the longest 6-min walking distance (424 m vs 405 m vs 389 m vs 365 m), and the lowest CAT score (12.2 vs 13.7 vs 15.6 vs 17.5) among the four groups. ACO group had greater risk for first AE compared to the mild COPD group (HR, 1.683; 95% CI, 1.175-2.410). The moderate COPD and severe COPD group HR values were 1.587 (95% CI, 1.145-2.200) and 1.664 (95% CI, 1.203-2.302), respectively. In addition, St. George's Respiratory Questionnaire score (HR: 1.019; 95% CI, 1.014-1.024) and gastroesophageal reflux disease were independent factors associated with the first AE (HR: 1.535; 95% CI, 1.116-2.112).
Introduction
COPD is a heterogeneous disease characterized by progressive respiratory impairment and not fully reversible airway obstruction. 1 Because COPD not only shows diverse clinical manifestations and prognosis, but also requires different treatments, multiple phenotypes are proposed to compliment this heterogeneity. [2] [3] [4] Along with the classical phenotypes of chronic bronchitis and emphysema, 5 several additional variables related to the prognosis of COPD, including severity of airway limitation, demographics, radiographic findings, comorbidities and occurrence of acute exacerbation (AE) are proposed for categorization.
An AE-COPD occurs on average about 0.34-3.00 times per person per year. 8 Because AE-COPD is directly linked to high mortality and significant economic burden, 9, 10 its prediction is important. The most reliable predictor of AE-COPD is history of AE, and there is a specific patient population with intrinsic susceptibility to AE due to exposure to triggers. 11 Patients who experience more than two moderate to severe AE incidents per year are called frequent exacerbators and have distinct characteristics including severely impaired FEV 1 , dyspnea score, and physiological score with worse outcomes. 12 However, not much is known about the specific COPD subtype associated with AE occurrence based on the various clinical variables related to the occurrence of AE. Cluster analysis is a method of data mining by defining data groups (clusters) based on measured characteristics to identify representation in specific groups. 13 Because subtypes of COPD have commonly airflow limitations but different symptoms, demographics, and prognoses, cluster analysis is used to identify specific phenotypes. 14 The aim of this study was to identify specific COPD subtypes through cluster analysis of variables known to be associated with COPD prognosis and to evaluate the usefulness of these subtypes to predict the first AE in COPD.
Materials and methods

Study population
Among the total 2,480 subjects registered in the Korea COPD Subgroup Study (KOCOSS) cohort recruited from 45 study centers between December 2011 and October 2014, 15 1,641
were initially screened for our study. We excluded 569 subjects that lacked airway limitation (measured FEV 1 /FVC ≥0.7), baseline pulmonary function test data, and follow-up data for the occurrence of AE (Figure 1 Table 2 ). Hyperlipidemia (13.3% vs 17.0% vs 10.4% vs 9.3%, p=0.014), myocardial infarction (5.6% vs 7.1% vs 5.5% vs 2.3%, p=0.043), and atopic dermatitis (4.6% vs 4.8% vs 3.8% vs 2.9%) were the highest in the mild group, followed by the ACO group.
Results
Comparison of baseline demographics
Patients who were prescribed long-acting muscarinic antagonist (LAMA; 57.1% vs 58.8% vs 72.9% vs 77.3%, p<0.001) or inhaled corticosteroid (ICS) plus long-acting beta2 agonist (LABA; 29.6% vs 21.1% vs 49.6% vs 46.1%, p<0.001) were more frequent in the moderate and severe COPD groups compared to the ACO and mild COPD groups (Table 3 ). The rates of theophylline (33.1% vs 27.8% vs 36.6% vs 33.1%, p=0.015) and roflumilast (0.6% vs 0.4% vs 5.9% vs 0.6%, p<0.001) treatments were highest in the moderate COPD group and similar in the ACO and severe COPD groups.
Occurrence of AE
The median follow-up period was 18 months (interquartile range: 6 to 36 months), and the ACO group had the longest follow-up duration ( Figure 2B ). 
Discussion
Using age, BMI, smoking status, history of asthma, CAT score, FEV 1 , and DLco variables in clustering, we divided patients into the following four subtypes: ACO, mild, moderate, and severe COPD. The ACO group had the second-best FEV 1 and FVC values and the highest BMI and DLco. The ACO group also showed the lowest CAT and SGRQ scores and higher rates of asthma and GERD as comorbidities. The COPD subtypes were an independent predictor for first occurrence of AE with SGRQ and GERD, and our ACO group showed a significant 76.6% increase in the rate of AE, with 65.9% and 69.6% increases in the moderate and severe groups, respectively, compared with the mild group.
Our study demonstrated that phenotype is linked to the occurrence of AE through clustering analysis using seven clinical variables without the history of AE. Previous studies identified the frequent exacerbator phenotype based on the history of AE, because a history of AE is the most powerful predictor of AE. 11, 12, 21 The Exacerbations of COPD Patients (EXACO) study revealed the frequent exacerbator phenotype to have more impaired airflow limitation, respiratory symptoms, and daily activity limitations according to fouryear follow-up of AE frequency. 12 In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, frequent exacerbators also showed rapid decline in FEV 1 , the rate of GERD or heartburn symptoms, and elevated WBC counts compared with non- Abbreviations: BMI, body mass index; DLco, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; SpO 2 , oxygen saturation; CAT, COPD assessment test; SGRQ, St George's Respiratory Questionnaire; GERD, gastroesophageal reflux disease; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
frequent exacerbators. 11 However, the subtype related to the occurrence of AE based on clustering in our study showed mild airway limitation and respiratory symptoms and relatively high rates of asthma and GERD as comorbidities. These results suggest that, in addition to other factors known to be associated with AE, the ACO subtype of COPD seems to have a relationship with AE occurrence. The reason we named one of the four clusters as a putative "ACO" group in this study is as follows. Diagnosis of ACO requires partial but not complete reversibility of airway limitation (post-BD FEV 1 <80% predicted). 22 Non-impairment of DLco with post-BD FEV 1 <80% predicted in the putative ACO group could be evidence for non-existing emphysema. Among the four groups, the second-most common underlying diseases, asthma and atopic dermatitis, also supported the possibility of ACO. 23 In clinical practice, the diagnosis of ACO, which indicates coexisting COPD and asthma, is challenging because the standard validated diagnostic criteria are still controversial. 24 ACO patients are generally reported to have more frequent AE compared with pure COPD or asthma. [25] [26] [27] [28] However, ACO patients in a previous study showed relatively severe airway limitation with impaired baseline post-BD FEV 1 , which is a strong risk factor for AE. 11 In our study, the putative ACO subtype had moderate airway limitation but a high rate of AE-COPD. In addition, our ACO group showed different characteristics from the ACO groups as defined in other studies, showing a low level of inflammatory markers and modest airway limitation and preserved functional capacity. [27] [28] [29] In addition, better dyspnea scale score and functional parameters in the ACO group are also unique to our study compared with those in other studies. These results suggest that other factors are related to the occurrence of AE in addition to the conventional COPD severity indicators. According to our study, the putative ACO group had the highest proportion of patients with GERD but lower proportions of patients who received LAMA and ICS plus LABA treatment due to mild airway limitation. The high AE occurrence rate in the ACO group might be attributed to the high presence of GERD despite relatively mild impairment of lung function. Several studies have reported that GERD is an independent risk factor for AE-COPD. 11, [30] [31] [32] [33] [34] [35] In the ECLIPSE study, AE-COPD was linked to the history of GERD or heartburn with prior history of AE. 11 Meta-analysis based on five prospective and retrospective COPD studies also demonstrated that the risk of AE-COPD was significantly increased in patients with GERD (relative risk: 7.57; 95% CI, 3.57-14.94). 30 Martinez et al demonstrated a significant relationship between the frequent exacerbator phenotype (≥2 COPD-AE per year) and GERD (odds ratio, 1.40; p=0.006). 35 However, since most COPD patients with GERD rarely complain of either reflux symptoms (eg, heartburn, regurgitation) or respiratory symptoms (eg, cough, dyspnea), 36 there is a possibility that GERD diagnosis often is overlooked. Silent aspiration of gastric contents due to GERD might lead to frequent AE-COPD by increasing bacterial burden in the respiratory tract. 37 Sasaki et al showed that
anti-reflux treatment significantly reduced the occurrence of AE in COPD patients without reflux symptoms, 38 indicating that management of GERD could be beneficial for preventing AE-COPD. Another reason for the high incidence of AE in our putative ACO group might be the low administration of ICS plus LABA, despite the relatively high proportion of asthma. Current Global Initiative for Asthma management guidelines recommend regular use of low-dose ICS as initial treatment for symptomatic asthma patients. Furthermore, if the predominance of asthma and COPD in ACO patients is difficult to determine, first-line treatment should include ICS, followed by addition of other inhalers if needed. 39 In our study, ICS usage in the ACO group was low, which might be due to mild impairment of lung function, good exercise capacity, and low symptom score. While the ACO group in our study was an independent factor for first AE occurrence, the annual incidence of AE was highest in the severe group. Although we did not collect data on changes in medication during follow-up, these findings suggest that the ACO group might have experienced inhibition of further development of AE by appropriate treatment such as ICS after occurrence of the first AE event.
The limitations of our study are as follows. First, AE in our study was not based on strict criteria since this was a retrospective cohort study. The accurate time, severity, and clinical course of AE were not evaluated. However, the occurrence of AE was carefully assessed by experienced pulmonologists, and all patients were evaluated at 6-month intervals. Second, the relatively short follow-up duration might result in underestimated AE occurrence; however, since the annual exacerbation frequency ranged from two to three times per year depending on the severity of COPD, 40 the median 18-month follow-up duration might be sufficient to assess the first development of AE. Lastly, subjects excluded due to insufficient follow-up data (n=470) might have led to selection bias. It was not possible to assume the cause of follow-up loss, but it might be another reason for underestimation of AE development.
Conclusion
In conclusion, we identified the COPD subtypes susceptible to AE using cluster analysis with several clinical factors, including lung function. The ACO group had frequent AE-COPD despite good pulmonary function and exercise capacity and low dyspnea scale, which might be associated with GERD. Thus, subtypes susceptible to AE need more aggressive treatment strategies considering their comorbidities. Further studies should highlight the specific phenotype related to mortality or lung function decline in COPD patients.
